FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy - STAT
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.
Search Group
Share To
Comments
About Screade
Screade® Inc. version be4f997, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments